We focused on this example and showed that recombinant antibodies to CDCP1 can be used to selectively deliver therapeutic cytotoxic payloads or recruit and activate T-cells to pancreatic cancer cells while sparing normal control cells. This evidence concerns the gene CDCP1 and familial pancreatic carcinoma.